Optimizing DLBCL Treatment: An Expert Roundtable on the Role of New and Emerging Targeted Therapies

Content Format:

Slideset

Credit Type:

--

Credits:

--
Guida del paziente agli ultimi progressi clinici nelle nuove terapie per la leucemia linfatica cronica o il linfoma linfocitico piccolo recidivante/refrattario

Content Format:

PDF

Credit Type:

--

Credits:

--
Guida del paziente agli ultimi progressi clinici nelle nuove terapie per la leucemia linfatica cronica o il linfoma linfocitico piccolo recidivante/refrattario

Content Format:

PDF

Credit Type:

--

Credits:

--
Guida del paziente agli ultimi progressi clinici nelle nuove terapie per la leucemia linfatica cronica o il linfoma linfocitico piccolo recidivante/refrattario

Content Format:

PDF

Credit Type:

--

Credits:

--
Guida del paziente agli ultimi progressi clinici nelle nuove terapie per la leucemia linfatica cronica o il linfoma linfocitico piccolo recidivante/refrattario

Content Format:

PDF

Credit Type:

--

Credits:

--
Guida del paziente agli ultimi progressi clinici nelle nuove terapie per la leucemia linfatica cronica o il linfoma linfocitico piccolo recidivante/refrattario

Content Format:

PDF

Credit Type:

--

Credits:

--
Guida del paziente agli ultimi progressi clinici nelle nuove terapie per la leucemia linfatica cronica o il linfoma linfocitico piccolo recidivante/refrattario

Content Format:

PDF

Credit Type:

--

Credits:

--
BTK Degrader Bexobrutideg in Patients With Relapsed/Refractory CLL/SLL

Content Format:

Video

Credit Type:

AMA

Credits:

0.25
Second-line Pirtobrutinib in CLL/SLL After Covalent BTKi Treatment: A Pooled Analysis of BRUIN LOXO-BTK18001 and BRUIN CLL-321

Content Format:

Video

Credit Type:

AMA

Credits:

0.25
CaDAnCe-101 Phase I Study of the BTK Degrader BGB-16673 in R/R CLL/SLL

Content Format:

Video

Credit Type:

AMA

Credits:

0.25
BRUIN CLL-314: Pirtobrutinib vs Ibrutinib in Treatment-Naive and BTKi-Naive R/R CLL/SLL

Content Format:

Video

Credit Type:

AMA

Credits:

0.25
Final Analysis of the Phase I/II BRUIN Trial of Pirtobrutinib in Patients With CLL/SLL Previously Treated with a Covalent BTKi

Content Format:

Conference Coverage

Credit Type:

AMA

Credits:

0.25
ALPINE Long-term Extension Study of Zanubrutinib in Relapsed or Refractory CLL/SLL

Content Format:

Conference Coverage

Credit Type:

AMA

Credits:

0.25
Congress to Clinic: Expert Perspectives on Therapeutic Advances and Practice Changing Data Emerging From the 2025 EHA and ICML Congresses

Content Format:

Text Module

Credit Type:

AMA

Credits:

1.00
Congress to Clinic: Expert Perspectives on Therapeutic Advances and Practice Changing Data Emerging From the 2025 EHA and ICML Congresses

Content Format:

Slideset

Credit Type:

--

Credits:

--
Evolving Paradigms in Hematologic Malignancies: Expert Insights on 6 Key Abstracts From EHA and ICML 2025

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
Key Advances in Lymphomas and Acute Lymphocytic Leukemia From EHA and ICML 2025

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
Applying Data to Practice: BTK Inhibitor Therapies to Treat CLL and MCL

Content Format:

Video

Credit Type:

AMA

Credits:

1.00
2023 Global Conference Coverage Updates on BTK Inhibitors for CLL and MCL

Content Format:

Slideset

Credit Type:

--

Credits:

--